SLS — SELLAS Life Sciences Group, Inc. stock price, charts and financials

Latest market price

11.22

+1.21+12.09%

Overview Short InterestFilings

SLSQT92SELLAS Life Sciences Group, Inc.·NASDAQ

Overview Short InterestFilings

11.22+12.09%

News

Up 12.1% — SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst (seekingalpha.com).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 FTRE-1.20%$18.94 IOVA+6.14%$4.32 MRVI-2.28%$6.42 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-970.31	Insider Own	10.60%	Shs Outstand	186.03M	Perf Week	-11.57%

Market Cap	1.86B	Forward P/E	-	EPS next Y	-0.12	Insider Trans	0.00%	Shs Float	183.79M	Perf Month	-24.57%

Enterprise Value	1.76B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	30.08%	Perf Quarter	102.22%

Income	-31.84M	P/S	0.00	EPS this Y	99.98%	Inst Trans	-	Short Ratio	6.05	Perf Half Y	157.33%

Sales	11.00M	P/B	16.07	EPS next Y	40.48%	ROA	-25.80%	Short Interest	55.28M	Perf YTD	165.52%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-47.12%	52W High	17.80 -36.96%	Perf Year	503.01%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-29.06%	52W Low	1.56 620.14%	Perf 3Y	510.37%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	9.74% 10.54%	Perf 5Y	14.01%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-193962.00%	Oper. Margin	0.00%	ATR (14)	1.25	Perf 10Y	-99.93%

Dividend Ex-Date	-	Quick Ratio	17.22	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	41.99	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	17.22	EPS Q/Q	28.57%	SMA20	-17.84%	Beta	2.46	Target Price	25.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-4.42%	Rel Volume	0.52	Prev Close	10.01

Employees	13	LT Debt/Eq	0.20	Earnings	Aug 06	SMA200	85.30%	Avg Volume	9.58M	Price	11.22

IPO Date	Mar 12, 2008	Option/Short	Yes / Yes	EPS/Sales Surpr.	16.67% -	Net Debt/EBITDA	4.75	Volume	5,012,606	Change	12.09%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-06-26	Reiterated	Industrial Alliance Securities		$10 → $25
Nov-15-22	Reiterated	Industrial Alliance Securities		$8.00
Jun-28-22	Reiterated	Cantor Fitzgerald	Overweight	$6.00
Nov-15-19	Upgrade	Maxim Group	Hold → Buy
Mar-19-18	Upgrade	Maxim Group	Hold → Buy

Latest News

Aug-02-26

Aug-02-2610:22AM

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalystseekingalpha.com

Jul-27-26

Jul-27-2604:42PM

SELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal FeesBenzinga

Jul-21-26

Jul-21-2601:35PM

10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga

Jul-17-26

Jul-17-2601:05PM

12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga

Jul-14-26

Jul-14-2603:06PM

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Upseekingalpha.com

Jul-09-26

Jul-09-2611:28AM

Sellas Life Sciences: REGAL Trial's Delayed Events Signal Selection BiasSeekingAlpha

Jul-08-26

Jul-08-2611:09AM

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wallbenzinga.com

Jun-30-26

Jun-30-2601:55PM

Why Sellas Remains A Strong Sell After Doubling In PriceSeekingAlpha

09:39AM

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?benzinga.com

09:00AM

Amentum Wins NASA'S COSMOS Contract to Advance Spaceflight Mission Operationsgurufocus.com

Jun-27-26

Jun-27-2604:25AM

Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Eventseekingalpha.com

Jun-26-26

Jun-26-2610:54AM

SELLAS Stock Hits New Highs: What's Happening Today?Benzinga

10:18AM

Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On FridayBenzinga

Jun-25-26

Jun-25-2602:07PM

Why SELLAS Life Sciences Stock Is Surging ThursdayBenzinga

01:05PM

12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga

Company

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	11	0	0	0	1	8	2	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	9	0	0	0	1	7	2	0	0
Selling, General and Administrative Excl. Other	21	12	12	14	13	11	10	10	13
Research and Development	26	16	19	24	30	21	9	10	18
Other Operating Expense	5	0	1	0	0	1	0	0	1
Operating Income	-46	-28	-32	-38	-42	-25	-17	-20	-32
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	1	1	1	1	4	0	1	3
Net Income Before Taxes	-35	-27	-31	-37	-41	-21	-17	-19	-29
Income Taxes	-4	0	0	0	0	0	0	0	-1
Consolidated Net Income	-41	-27	-31	-37	-41	-21	-17	-19	-28
Net Income From Continuing Operations	-33	-27	-31	-37	-41	-21	-17	-19	-28
Net Income	-41	-27	-31	-37	-41	-21	-17	-19	-28
EPS (Recurring)	-970.31	-0.25	-0.50	-1.34	-2.13	-1.34	-2.11	-10.92	-157.72
EPS (Basic, Before Extraordinaries)	-970.31	-0.25	-0.50	-1.34	-2.13	-1.34	-2.11	-10.92	-157.72
EPS (Diluted)	-970.31	-0.25	-0.50	-1.34	-2.13	-1.34	-2.11	-10.92	-157.72
EBITDA	-39	-27	1	1	-31	-18	-16	0	0
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	44.84	10.37	23.24	—	—
Gross Margin	81.82	—	—	—	100.00	87.50	100.00	—	—
Operating Margin	-418.18	—	—	—	-4,200.00	-312.50	-850.00	—	—
Net Margin	-372.73	—	—	—	-4,100.00	-262.50	-850.00	—	—
Shares Outstanding	0	109	61	28	19	15	8	2	0
Market Capitalization	—	411	63	30	45	83	46	9	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalin Katherine Bach	Director	Nov 19 '25	Buy	1.59	63,400	100,806	104,400	Nov 21
VAN NOSTRAND ROBERT L	Director	Jun 12 '25	Buy	1.48	10,000	14,800	20,400	Jun 13
Wasman Jane	Director	May 30 '25	Buy	1.69	20,000	33,800	30,400	Jun 02
Kalin Katherine Bach	Director	May 22 '25	Buy	1.80	20,000	36,000	41,000	May 22
Stergiou Angelos M.	President and CEO	Dec 05 '22	Sale	2.61	6,494	16,938	161,689	Dec 05
Burns John Thomas	Senior VP, Finance & CAO	Dec 05 '22	Sale	2.59	1,159	3,002	29,347	Dec 05
WOOD BARBARA A	EVP, Gen. Counsel, Corp. Sec.	Dec 05 '22	Sale	2.59	2,153	5,576	56,344	Dec 05
Stergiou Angelos M.	President and CEO	Dec 02 '21	Sale	6.25	2,120	13,252	121,167	Dec 03
WOOD BARBARA A	EVP, Gen. Counsel, Corp. Sec.	Dec 02 '21	Sale	6.25	847	5,298	42,028	Dec 03
Burns John Thomas	VP, Finance & Corp Controller	Dec 02 '21	Sale	6.27	231	1,448	17,644	Dec 03
Stergiou Angelos M.	President and CEO	Dec 31 '18	Sale	1.25	23,277	29,189	426,858	Jan 03
Nisi Rudolph	Director	Jun 20 '17	Sale	0.55	500	273	14,864	Jun 22
Hudson Bay Capital Management LP	10% Owner	Feb 08 '17	Sale	0.84	2,363,441	1,985,290	2,036,559	Feb 10
Hudson Bay Capital Management LP	10% Owner	Feb 08 '17	Buy	1.00	1,100	1,100	0	Feb 10
KRIEGSMAN STEVEN A	Director	Jan 23 '14	Option Exercise	1.56	150,000	233,500	155,000	Apr 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.